TEAM

Meet the people behind Gero

Peter Fedichev, PhD

CEO, Co-Founder

Physicist-turned-biotech innovator, Peter Fedichev is the CEO of Gero, a company he co-founded to combat aging and complex diseases. A top-cited physicist with a PhD from the University of Amsterdam and over 75 publications, he uses his deep expertise in physics and data science to drive innovation at the intersection of AI and human health, leveraging over 20 years of experience.

Max Kholin

Co-founder, Chief Corporate Development Officer

Biotech entrepreneur with 20+ years of experience, Max co-founded Gero to fight aging and age-related disease. He leads corporate affairs, legal strategy, fundraising, and investor relations, holding master's degrees in law and economics. He has initiated and closed multiple partnering, licensing, and investment deals, driven by a mission to extend healthy human lifespan through science-enabled progress.

Eileen Brandenburger, PhD

Head of Intellectual Property and Licensing

Eileen is leading the company's commercial and technical IP legal work. Eileen previously worked in the same capacity at NASDAQ listed TechBio company Exscientia AI (now Recursion Pharmaceuticals).

Jason Brown, PhD

Head of Business Development

Jason Brown leads partnering and out-licensing across Gero’s target discovery and generative chemistry platforms and therapeutic programs. His leadership experience spans pharmaceutical R&D, biotechnology and discovery services, including roles at Pfizer and Evotec, where he partnered AI drug discovery platforms with pharmaceutical companies. Most recently, he served as chief business officer at IMU Biosciences, leading business development for an AI-driven immune profiling platform built on large-scale human immune data. Jason holds a PhD in Biochemistry from the University of Cambridge.

Amir Feizi, PhD

Head of Translational AI and Discovery

Amir Feizi heads Gero's translational AI and target discovery strategy, leading the integration of physics-based longitudinal health models, human genetics, and experimental biology to identify disease-driving mechanisms and advance therapeutic discovery. A scientific leader with a track record spanning Novo Nordisk and OMass Therapeutics, Amir has built and directed genetics-driven drug discovery capabilities across cardiometabolic and inflammatory diseases. At OMass, he established and led bioinformatics, contributing to an inflammatory bowel disease program subsequently licensed to Genentech. At Novo Nordisk, he advanced AI-enabled approaches to therapeutic target identification in Type 2 Diabetes and MASH. Amir holds a PhD from Chalmers University of Technology and has authored more than 20 scientific publications, including research in Science, Nature, and Cell.

Anton Malyshev, PhD

Head of ProtoBind

Anton leads Gero's generative AI drug discovery platform, ProtoBind, overseeing platform strategy, operations, and the advancement of hit discovery programs and pharmaceutical partnerships. A biotechnology executive with over a decade of experience in drug development and commercialization, Anton founded and served as CEO of Lactocore, where he built a multidisciplinary R&D organization, advanced two peptide therapeutics to IND-ready status, and secured strategic partnerships and licensing opportunities. Previously, at Optic, an AI-driven pharmaceutical technology company, he directed portfolio strategy and business development, integrating AI-enabled asset evaluation with therapeutic pipeline development. Anton holds a PhD in Neurophysiology from Lomonosov Moscow State University.

Paulette Greenidge, PhD

Program Lead Medicinal Chemistry

Paulette Greenidge leads medicinal chemistry at Gero, bringing more than 25 years of expertise in computational drug design and pharmaceutical R&D to the advancement of AI-discovered therapeutics. Previously, she held scientific leadership roles at Novartis, contributing to drug candidates across oncology, immunology, and respiratory diseases. She advanced structure-based drug discovery programs at Sprint Bioscience, subsequently acquired by Gilead Sciences, and at Sitryx Therapeutics, subsequently licensed to Boehringer Ingelheim. A Fellow of the Royal Society of Chemistry, Paulette holds a PhD in Theoretical Chemistry from the University of Manchester and is credited with 11 granted patents and 22 peer-reviewed publications.

Olga Burmistrova PhD

Preclinical Program Lead

Olga leads preclinical research and external R&D collaborations at Gero, supporting the advancement of the company’s therapeutic pipeline. With a Ph.D. in molecular biology, she brings deep expertise in target validation, pharmacology, translational biology, and experimental drug development. She has authored multiple peer-reviewed publications and has extensive experience managing complex preclinical programs across academia and industry. Olga is deeply interested in the biology of aging and is passionate about driving innovative translational projects that have the potential to extend healthy lifespan.

Jérémie Zumer, PhD

AI/ML Translational Science Lead

Jérémie leads the development of Gero's longitudinal health foundation models, directing AI research, data strategy, and next-generation deep learning capabilities for therapeutic target discovery. Previously, at IONLACE, he led a multidisciplinary team developing an AI-powered nanobody design platform that achieved a 100-fold improvement in laboratory-confirmed binding success rates against benchmark methods. At Microsoft Research, he advanced patented conversational AI technologies, with models deployed at scale. He also held a research role at Maluuba, subsequently acquired by Microsoft. Jérémie holds a PhD in Bioinformatics from the Université de Montréal and a master's degree in deep learning from Mila, the research institute co-founded by Turing Award laureate Yoshua Bengio.

Konstantin Avchaciov

AI/ML Translational Science Lead

Konstantin leads the computational design of molecules against validated disease targets. He led the building of proprietary AI frameworks, including ProtoBind and HARVEST, and spearheaded data engineering and predictive model prototyping for Gero’s drug discovery collaborations. His research has accumulated nearly 600 citations with an h-index of 12, featuring high-impact publications in journals such as Nature Communications, Scientific Reports, and Aging Cell. Konstantin’s landmark scientific contributions include uncovering the progressive loss of resilience that defines the human lifespan limit, pioneering hybrid quantum-classical ML models for generative chemistry, and demonstrating AI-driven polypharmacological compounds that extend organismal lifespan. Konstantin holds a PhD in Materials Science from the University of Helsinki, where his research focused on molecular dynamics simulations of non-equilibrium systems, and an MS in Quantum Physics and Nanotechnology from the National Research University of Electronic Technology.

Sodbo Sharapov, PhD

Statistical Genetics Lead

Sodbo Sharapov leads statistical genetics at Gero, applying human genetic evidence to target discovery and prioritization. He brings 12 years of experience applying human genetics to disease biology and drug discovery. At the Human Technopole Genomics Center in Milan, he led drug discovery and repurposing analyses and contributed to large-scale fine-mapping and colocalization pipelines to identify genes and proteins implicated in disease. His research has mapped genetic architecture across immune-cell gene expression, the human plasma proteome and AI-derived cardiac MRI traits.

Mina Nguyen

Head of Communications

Mina leads Gero's corporate communications strategy, shaping its reputation, scientific positioning, and engagement with pharmaceutical partners, investors, and industry stakeholders. Mina has held senior communications roles across pharmaceuticals, biotechnology, and healthcare, including Pfizer Oncology, Seagen, and Ionis Pharmaceuticals. She has directed communications supporting pivotal Phase 3 clinical results, multiple FDA approvals, and oncology product launches. Her experience also spans genomics at Illumina and healthcare communications at Kaiser Permanente, where she led communications for physicians, hospitals, and health plan operations. Mina holds a BA in Journalism from San Diego State University.